August 7, 2018
Big data are ushering in a new era of individualized cancer care and prevention, but not without conceptual and practical challenges. Canadian advances in genomics will be made by or limited by bioinformatics analytical capacity as well as the ability to store and analyze data in new and more sophisticated ways.
To help realize the potential of genomics research in cancer, the Canadian Data Integration Centre (CDIC) platform, led by OICR, offers third generation bioinformatics and genomics tools to support both functional and clinical genomics research. CDIC is the largest academic cancer informatics program in the country – offering customizable, client-oriented access services for data challenges across diverse research areas.
July 10, 2018
Acute myeloid leukemia (AML) progresses quickly and requires treatment soon after diagnosis, but the disease begins long before becoming symptomatic. Early indicators of AML were thought to be indistinguishable from healthy aging. But now, an international group of researchers led in part by Dr. Sagi Abelson, a postdoctoral fellow in the lab of Dr. John Dick at the Princess Margaret Cancer Centre, has discovered distinctive traces of AML in patients up to 10 years before they were diagnosed with the disease.
June 19, 2018
Over the past 10 years, more than 300,000 Canadians have volunteered to be part of the Canadian Partnership for Tomorrow Project (CPTP), a research platform that tracks the development of cancers and chronic diseases in the population over several decades to better understand risk factors.
Researchers from across Canada and the University of Toronto published a manuscript in the Canadian Medical Association Journal last week, marking a culmination of effort from hundreds of Canadian researchers to build the project with support from multiple national and provincial funders.
March 29, 2018
Q and A with Dr. Philip Awadalla, Scientific Director of the Canadian Partnership for Tomorrow Project
Since 2008, the Canadian Partnership for Tomorrow Project (CPTP) has collected health data and biological samples from more than 300,000 volunteer participants across Canada. Now that its primary data collection phase has concluded, the Project is sharing this data with qualified researchers to help uncover the factors behind cancer and other diseases. It was recently announced that OICR’s Dr. Philip Awadalla will serve as the Project’s National Scientific Director and that OICR will host the Project’s national database and other scientific activities. We sat down with Awadalla to learn more about his vision for CPTP’s future. Continue reading – Q and A with Dr. Philip Awadalla, Scientific Director of the Canadian Partnership for Tomorrow Project
March 29, 2018
Canada’s largest health research platform teams up with University of Toronto to accelerate cancer and chronic disease research
Pictured (left to right): Dr. John Mc Laughlin, Executive Director of CPTP; Cindy Morton, Chief Executive Officer of the Canadian Partnership Against Cancer.; and Dr. Philip Awadalla, National Scientific Director of CPTP.
Canadian Partnership for Tomorrow Project (CPTP) enters a new era of scientific activity under the leadership of newly appointed National Scientific Director, Dr. Philip Awadalla
March 29, 2018 (Toronto) – The Canadian Partnership Against Cancer (“the Partnership”) today announced The University of Toronto’s Dalla Lana School of Public Health will be the new national scientific partner of the Canadian Partnership for Tomorrow Project (CPTP) – Canada’s national population cohort for precision health. This new scientific partner will enable a strong national scientific vision for CPTP and support leading-edge research on the possible causes of cancer and chronic diseases, leading to more made-in-Canada discoveries and breakthroughs. In addition, the University has announced that Ontario Institute for Cancer Research (OICR) will be its strategic partner to deliver the expertise and services needed to lead this key research platform.
March 6, 2018
Study shows that environmental exposures such as air pollution are more determinant of respiratory health than inherited genetics
Toronto (March 6, 2018) – Researchers have found strong evidence that environmental exposures, including air pollution, affect gene expressions associated with respiratory diseases much more than genetic ancestry. The study, published today in Nature Communications, analyzed more than 1.6 million data points from biological specimens, health questionnaires and environmental datasets, making this study one of the largest ever to examine the relationship between gene expression and environmental stimuli. These findings represent a groundbreaking use of big data to uncover the environmental factors that are behind diseases and inform strategies for prevention, an approach that would apply to a number of diseases, including cancer.
January 25, 2018
The Canadian Data Integration Centre receives new funding to help cancer researchers translate findings to patients
Toronto (January 25, 2018) – The Canadian Data Integration Centre (CDIC) has received $6.4 million in funding from Genome Canada to help the research community translate the biological insights gained from genomics research into tangible improvements for cancer patients.
CDIC is a “one-stop shop” service delivery platform for cancer researchers, helping streamline research by providing coordinated expertise on a broad range of services, including data integration, genomics, pathology, biospecimen handling and advanced sequencing technologies. It is an international leader in genomics, bioinformatics and translational research, supporting some of the world’s largest programs in genomic data analysis, genomic and clinical data hosting, cancer data analyses and access, and the development of algorithms for advanced sequencing technology.
May 3, 2017
The advent of genomic sequencing and targeted therapies has opened the door to new ways of diagnosing and treating cancer. The Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) program is a new, province-wide initiative supported by OICR that will allow more patients to benefit from these innovations while also helping to advance cancer research in Ontario.
January 17, 2017
For scientists working to understand diseases and develop new treatments, access to data is key. Ontario Health Study (OHS) participants have already provided the Study with a wealth of information about their health and lifestyle through the OHS online survey, and in some cases, blood samples and physical measures. Researchers can use this information to uncover the causes of various chronic diseases and to inform further research. Now, OHS participants are being given an opportunity to further help researchers by completing a follow-up questionnaire.
May 13, 2016
OICR researcher receives $2 million in federal funding to study metabolic conditions that can lead to cancer
Dr. Philip Awadalla and the Ontario Health Study team.
Chronic health conditions place a heavy burden on patients and their families, and cost the healthcare system and the Canadian economy staggering amounts. Chronic diseases were behind 67 per cent of total direct costs in health care and 60 per cent of total indirect costs as a result of early death, loss of productivity and foregone income, according to a 2006 study by the Public Health Agency of Canada. Globally, non-communicable disease (NCD) was made a priority by the World Health Organization, leading to the formation of the NCD Alliance and the Sharjah Declaration, which aims to reduce the global burden of NCDs.
May 2, 2016
$2 million in new funding from Canadian Institutes of Health Research will help Ontario team study metabolic syndromes
Toronto (May 2, 2016) – Dr. Philip Awadalla, Senior Investigator at the Ontario Institute for Cancer Research and Principal Investigator for the Ontario Health Study has been awarded $2 million by the Canadian Institutes of Health Research (CIHR). The award will fund the study of the role of both genes and the environment on the development of metabolic syndrome, a cluster of medical conditions that are common in aging adults, including obesity, hypertension, high cholesterol, high blood sugar and insulin resistance.
These conditions are considered to be both risk factors and causal factors in the development of cancer and chronic diseases like heart disease, stroke and diabetes. A better understanding of how to prevent and treat the conditions of metabolic syndrome could also help in the design of new strategies to prevent these diseases before they develop.
December 1, 2015
The rise of genomics has provided scientists in many fields with insights that would not have been possible only a couple of decades ago. When Dr. Philip Awadalla first became interested in molecular genetics and evolution, genome technologies were just beginning to come to the fore.
“We didn’t have a human genome sequenced yet – the Human Genome Project was not completed – and we were still trying to answer very basic questions, like how many genes do humans have or which genes are important,” says Awadalla, who recently joined OICR as a Principal Investigator. “However, these basic questions are important, because both genomics and the mathematical models for understanding how it functions are the underpinning of all the tools we use in every field of genomics. You can’t understand how a genome works unless you understand where it came from.”